<DOC>
	<DOCNO>NCT01777477</DOCNO>
	<brief_summary>The purpose study evaluate safety define maximum tolerate dose ( MTD ) Choloroquine combine Gemcitabine , evaluate preliminary efficacy combine systemic Gemcitabine Chloroquine . In addition , influence treatment anti-cancer immunity value GOLPH2 serum marker pancreatic cancer assess within translational objective . - Trial medicinal product</brief_summary>
	<brief_title>Adjuvant Effect Chloroquine Gemcitabine</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm nonresectable locally advanced metastatic adenocarcinoma pancreas . Assessment do within 21 day enrolment . Age = 18 year Adequate liver function kidney function test , include follow : Bilirubin &lt; 2 x ULN , AlaninAminotransferase ( ALT ) &lt; 5 x ULN , Alcaline phosphatase &lt; 5 x ULN , Estimated creatinine clearance &gt; 40 ml/min ( use Cockroft formula ) Adequate haematological value : Haemoglobin &gt; 80 g/L , Leukocytes &gt; 3.00 g/L , Neutrophils &gt; 1.00 g/L , Platelets &gt; 100 g/L Written inform consent Biliary decompression mandatory inclusion study case bilirubin level &gt; 50 Âµmol/L . Women breastfeed use effective contraception sexually active , pregnant agree become pregnant 12 month thereafter . A negative pregnancy test inclusion trial require woman childbearing potential , define reach menopause , last menstrual period occur less 12 month ago , surgical sterilization perform , fallopian tube and/or uterus surgically remove . Men agree father child participation trial 12 month thereafter . Patient compliance geographic proximity allow proper stag followup . Patient eligible FOLFIRINOX treatment . WHO PS 02 Exclusion criterion : Life expectancy &lt; 3 month Severe medical psychiatric comorbidity prohibit plan treatment give informed consent Any prior chemotherapy pancreatic cancer , include adjuvant chemotherapy . Any prior radiotherapy combine radiochemotherapy pancreatic cancer complete less 12 month prior study inclusion . Known hypersensitivity trial drug hypersensitivity component trial drug . Known glucose6phosphate dehydrogenase deficiency . Concurrent use experimental drug , treatment within clinical trial within 30 day prior trial entry . Active heart disease define congestive heart failure &gt; NYHA class 2 Past current history ( within last 2 year prior treatment start ) malignancies except basal squamous cell carcinoma skin situ carcinoma cervix Inability unwillingness comply study protocol No understanding german language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>